Ad is loading...
MDOBX
Price
$9.79
Change
-$0.07 (-0.71%)
Updated
Nov 15 closing price
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
Ad is loading...

MDOBX vs RNWFX

Header iconMDOBX vs RNWFX Comparison
Open Charts MDOBX vs RNWFXBanner chart's image
Morgan Stanley Developing Opportunity C
Price$9.79
Change-$0.07 (-0.71%)
VolumeN/A
CapitalizationN/A
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
MDOBX vs RNWFX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MDOBX vs. RNWFX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MDOBX is a StrongBuy and RNWFX is a Buy.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. MDOBX (34M). RNWFX pays higher dividends than MDOBX: RNWFX (1.51) vs MDOBX (0.00). MDOBX was incepted earlier than RNWFX: MDOBX (5 years) vs RNWFX (23 years). RNWFX is a more actively managed with annual turnover of: 32.00 vs. MDOBX (15.00). RNWFX has a lower initial minimum investment than MDOBX: RNWFX (250) vs MDOBX (1000). MDOBX annual gain was more profitable for investors over the last year : 22.38 vs. RNWFX (11.54).
MDOBXRNWFXMDOBX / RNWFX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence5 years23 years-
Gain YTD18.0947.099255%
Front LoadN/AN/A-
Min. Initial Investment1000250400%
Min. Initial Investment IRAN/AN/A-
Net Assets34M60.9B0%
Annual Yield % from dividends0.001.51-
Returns for 1 year22.3811.54194%
Returns for 3 years-23.87-14.55164%
Returns for 5 yearsN/A17.17-
Returns for 10 yearsN/A41.00-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics